- In November 2023, Hovione announced the expansion of its nasal drug delivery portfolio through the launch of innovative nasal powder delivery devices, developed in collaboration with IDC. This development aims to offer a more effective and patient-friendly alternative to conventional drug delivery methods. By enabling rapid and safe administration for both local and systemic therapies, it enhances treatment outcomes and supports broader adoption of nasal drug delivery technologies in the pharmaceutical market
- In July 2021, GSK plc received approval from the U.S. Food and Drug Administration for Nucala (mepolizumab), a monoclonal antibody designed to treat chronic rhinosinusitis with nasal polyps. This approval introduces a targeted biologic therapy that addresses a significant unmet medical need. The development enhances treatment options, potentially improving quality of life for patients while strengthening GSK’s position in the specialty respiratory treatment segment
